Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations? POTCAST challenges our fear of potassium.
Check out the VA by Jeyakumar Meyyappan and join the #NephJC conversation
VALIANT: The Visual Abstract
The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-complex MPGN. This trial builds on prior upstream complement strategies and strengthens the case for disease-targeted therapy in C3G.
Check out the VA Dr. Akshaya Jayachandran and don´t forget to join #NephJC on bluesky.
LIBERATE-D: The Visual Abstract
In patients with dialysis-dependent acute kidney injury, a conservative dialysis strategy was evaluated in the LIBERATE-D trial. Could less be more? Join the discussion in #NephJC, but first, check out the VA created by Sejal Lakhani
PISCES: The Visual Abstract
Curious how n-3 PUFAs may cut serious cardiovascular events in dialysis? 🐟
A big signal, a big dose, and a big discussion ahead — don’t miss this #NephJC!
Check out the VA made by our master Brian Rifkin
ORIGIN-3: The Visual Abstract
KDIGO 2025 IgA guidelines - Visual Abstract
KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection.
Check out the visual abstract created by Natalia Nombera
Protein supplementation in CKD: The Visual Abstract
Achieving immune tolerance by chimerism in kidney transplant
Is getting immunosuppression-free a chimera in kidney transplant?
Check out the visual abstract by Bogdan Agavriloaei
The AHA/ACC 2025 Hypertension Guidelines visual abstract
New updated guidance on hypertension including screening for secondary causes, use of renal denervation, hypertension and pregnancy, risk assessment, monitoring and treatment.
Check out this wonderful VA by Dr Sejal Lakhani
The ACHIEVE visual abstract
Does spironolactone decrease cardiovascular disease and heart failure hospitalizations in patients on dialysis?
Check out this crisp VA by Dr Akshaya Jayachandran.
The HiLo Trial - Visual Abstract
Is a lower versus higher phosphate target beneficial to patients undergoing hemodialysis?
Check out this crisp VA by Dr Sejal Lakhani
Insights from the CRIC Study: Visual Abstract
Based on data from the CRIC study, this analysis dives deep into whether this lab mismatch is just noise… or a clinical signal we’ve been missing.
Check out the beautiful visual abstract made by our NephJC interns Sai Vani Yellampalli and Akshaya Jayachandran. Great team work!!!
CONFIDENCE Visual Abstract
Check out the beautiful visual abstract made by NephJC intern Michelle Fravel.
CAPTIVATE NephTrials Visual Abstract
Check out the beautiful visual abstract made by Kajaree Giri
The NUDGE-CKD Visual Abstract
Check out the beautiful visual abstract made by NephJC faculty Dr Divyia Bajpai
The STAMP Trial VA: Who Gets the Approval—TAC or MMF in Pediatric Nephrotic Syndrome?
Nephrotic syndrome in kids can mean frequent relapses, high steroid burden, and tough treatment choices. So which helps maintain remission better: Tacrolimus or MMF?
See the Visual Abstract Krithika Mohan
TAC or MMF—what works better in pediatric nephrotic syndrome?
Nephrotic syndrome in children, especially those with frequent relapses or steroid dependence, remains a therapeutic challenge. The STAMP trial compared tacrolimus and mycophenolate mofetil to help guide treatment decisions.
Does Lorundrostat Effectively Lower Blood Pressure in Uncontrolled Hypertension?
Stunning visual abstract summarizing NEJM study, by Priti Meena
Patient with kidney disease under the knife: does desmopressin really plug the leak?
Can desmopressin reduce post-kidney biopsy bleeding? Visual abstract summarizing Kidney 360 article, by Cristina Popa
Desmopressin for kidney biopsy - The Visual abstract
Does desmopressin reduce the risjk of post kidney biopsy bleeding? Checkout the beautiful VA answering this practical question by NSMC faculty Dr Divya Bajpai.